Navigation Links
QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer
Date:3/31/2017

HILDEN, Germany and GERMANTOWN, Maryland, March 31, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it is commercializing the Research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer. QIAGEN has acquired an exclusive worldwide license from Johns Hopkins University for detecting the AR-V7 biomarker in all sample and cell types through nucleic acid tests such as polymerase chain reaction (PCR) or next-generation sequencing (NGS). Johns Hopkins researchers have used AdnaTest technology in studies to evaluate the expression of AR-V7 messenger RNA in prostate cancer patients.

"Our AdnaTest workflow unlocks an important biomarker for clinical research to provide for the development of prostate cancer diagnostics in the future. Providing accurate insights from circulating tumor cells in a blood sample, our AR-V7 solution is a significant addition to our portfolio of non-invasive liquid biopsies for Personalized Healthcare," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area. "We are pleased to partner with the pioneering researchers at Johns Hopkins in developing this workflow. We plan to make the AdnaTest kit commercially available this year, as a Sample to Insight solution for clinical researchers."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={55C014E9-91D1-4E5E-8FF0-822B2224081A}&lang=en

Contacts: 

QIAGEN 

Investor Relations            
John Gilardi    
+49-2103-29-11711        
e-mail: ir@QIAGEN.com             
           
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826  
e-mail: pr@QIAGEN.com


'/>"/>
SOURCE QIAGEN N.V.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows
2. New Study Published in Lancet Respiratory Medicine Highlights QIAGENs QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
3. QIAGENs QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits
4. How These Research Services Stocks are Faring? -- Myriad Genetics, Qiagen, INC Research, and La Quinta
5. QIAGEN Enhances Bioinformatics Portfolio with Acquisition of OmicSoft
6. QIAGEN Announces Comprehensive Range of Enhancements for GeneReader NGS System
7. Research and Markets - Global Cervical Cancer Diagnostic Testing Market Growth of 6%, 2016-2020 with Becton, Hologic & Qiagen Dominating
8. Research Reports Coverage on Services Stocks -- Myriad Genetics, Qiagen, INC Research, and La Quinta
9. QIAGEN GeneReader NGS System to Relaunch in U.S. Market
10. QIAGENs GeneReader NGS System Streamlines Data Management for Labs
11. QIAGEN führt Flüssigbiopsie-Workflow für das GeneReader NGS-System ein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
Breaking Medicine Technology:
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... ... ... Happened in the Garden of Eden”: retells the stories of three Bible figures in modern ... author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate the ... The facility was developed by Rendina as part of its ongoing relationship with ...
Breaking Medicine News(10 mins):